Seth M retweeted
hiring great people as a founder must be so hard
how do you convince people just as if not more smart than you to come work for you
Seth M retweeted
What is all the hate for Veritasium all of a sudden because he is going to be spending more time with his family?
The man has been educating people for more than a decade and this is how you treat him? Just because he decided to bring in a team to help him? Please just be mad at anything.
Just be happy to watch the videos I know you're not paying for.
Seth M retweeted
Today we’re thrilled to announce JAM-2 — the first AI model capable of generating drug-quality antibodies straight from the computer, with industry-leading success rates.
> Drug-like affinities: Picomolar to single-digit nanomolar antibody binders for half of 26 targets while testing <45 designs each.
> Unlocking hard targets: Up to 11% success rate for direct on-cell GPCR binders; top antibody hits in the single-digit nanomolar range.
> Unprecedented epitope breadth: JAM-2 routinely designed antibodies that hit 30–70% of user-defined epitopes, now enabling intentional design of biology — not chance discovery.
> Drug-like developability: Over 50% of antibody designs passed core industry developability criteria with zero optimization.
> Massive leverage: A four-person team prosecuted 16 targets in parallel in < 1 month.
JAM-2 is the first de novo antibody design capability ready for front-line use in drug discovery, matching or surpassing traditional discovery approaches.
We’re already deploying JAM-2 with multiple large pharma partners and seeing excellent results.
If you’re interested in partnering on molecule development or accessing JAM-2, contact [email protected].
Read more in our whitepaper (link below)









